Eli Lilly's weight-loss drug Zepbound and diabetes medication Mounjaro are no longer in short supply. That could limit ...

Eli Lilly's tirzepatide, sold as Zepbound for weight loss and Mounjaro ... companies that make cheaper copies of tirzepatide will face new restrictions on marketing those medications.

In a high-profile showdown Tuesday with Sen. Bernie Sanders’ Senate health committee, Novo Nordisk CEO Lars Fruergaard ...

About 40% of U.S. adults suffer from obesity, and the cost of covering GLP-1 agonists and related anti-obesity drugs can be ...

Research shows patients taking weight-loss drugs like Ozempic and Wegovy are more likely to have food left in the stomach or ...

The removal of Zepbound and Mounjaro from the regulator’s shortage list could lead to restrictions on pharmacies making ...

Metsera, a biotech focused on obesity treatments, came out of stealth only this year, and its lead drug is still in early ...